A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
SB-742457 is a 5HT6 receptor antagonist that is in development for the symptomatic treatment
of mild to moderate Alzheimer's disease . To date, all clinical trials have been conducted
using a capsule formulation of SB-742457. However, it is intended to conduct all futures
studies with a tablet formulation. The aim of this study is to assess the pharmacokinetic
profile of SB-742457 and its major metabolites following single doses of both the capsule and
tablet formulations.